Experimental Hematology
Volume 38, Issue 1 , Pages 1-2 , January 2010

Mouse MAPC-mediated immunomodulation: Cell-line dependent variation

  • Ariane Luyckx

      Affiliations

    • Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium
    • Drs. Luyckx and De Somer contributed equally to this work.
    • ,
  • Lien De Somer

      Affiliations

    • Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium
    • Drs. Luyckx and De Somer contributed equally to this work.
    • ,
  • Omer Rutgeerts

      Affiliations

    • Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium
    • ,
  • Mark Waer

      Affiliations

    • Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium
    • ,
  • Catherine M. Verfaillie

      Affiliations

    • Stem Cell Institute, University of Leuven, Leuven, Belgium
    • ,
  • Stefaan Van Gool

      Affiliations

    • Laboratory of Experimental Immunology, University of Leuven, Leuven, Belgium
    • ,
  • An D. Billiau

      Affiliations

    • Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium
    • Corresponding Author InformationOffprint requests to: An D. Billiau, M.D., Ph.D., Laboratory of Experimental Transplantation, Campus Gasthuisberg O&N I Box 811, Herestraat 49, Leuven 3000, Belgium

References 

  1. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499–3506
  2. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol. 2006;176:7761–7767
  3. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–1586
  4. Kovacsovics-Bankowski M, Streeter PR, Mauch KA, et al. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol. 2009;255:55–60
  5. Highfill SL, Kelly RM, O'Shaughnessy MJ, et al. Multipotent adult progenitor cells (MAPC) can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood. 2009;114:693–701
  6. Ulloa-Montoya F, Kidder BL, Pauwelyn KA, et al. Comparative transcriptome analysis of embryonic and adult stem cells with extended and limited differentiation capacity. Genome Biol. 2007;8:R163
  7. Serafini M, Dylla SJ, Oki M, et al. Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. J Exp Med. 2007;204:129–139
  8. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic stem cells. Stem Cells. 2008;26:89–98
  9. Le Blanc K, Rasmusson I, Götherström C, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20
  10. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114–2120

PII: S0301-472X(09)00400-7

doi: 10.1016/j.exphem.2009.10.009

Experimental Hematology
Volume 38, Issue 1 , Pages 1-2 , January 2010

Article Tools